Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sleepiness Clear all
Recruiting Phase 3 Interventional

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant tablet, Placebo tablet
Drug · Other
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
6 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 11, 2026, 10:26 PM EDT
Recruiting Not applicable Interventional

Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

NCT02703207
View directory record Official record
Conditions
Obstructive Sleep Apnea, OSA COPD Overlap Syndrome
Interventions
Positive airway pressure, NIPPV and /or oxygen
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Plant-based Diet on Postprandial Sleepiness

NCT05706649
View directory record Official record
Conditions
Drowsiness
Interventions
Plant-based diet
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management

NCT00801892
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2
Interventions
Continuous Positive Airway Pressure (CPAP), Sham- Continuous Positive Airway Pressure (Sham-CPAP)
Device
Lead sponsor
Eileen R. Chasens
Other
Eligibility
40 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 11, 2026, 10:26 PM EDT
Active, not recruiting Not applicable Interventional

Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease

NCT02909192
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Light Therapy Device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00107848
View directory record Official record
Conditions
Narcolepsy, Sleep Apnea, Obstructive
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 11, 2026, 10:26 PM EDT
Completed No phase listed Observational

Observational Study of LUMRYZ in Narcolepsy

NCT06792708
View directory record Official record
Conditions
Narcolepsy
Interventions
LUMRYZ
Drug
Lead sponsor
Avadel
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Bradenton, Florida • East Lansing, Michigan • Middletown, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT01681121
View directory record Official record
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 11, 2026, 10:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

NCT04618263
View directory record Official record
Conditions
Major Depressive Disorder, Excessive Sleepiness
Interventions
GATE-101
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 11, 2026, 10:26 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Not applicable Interventional Results available

Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children

NCT01554527
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Child Behavior Disorders, Attention Deficit Disorder With Hyperactivity, Disorders of Excessive Somnolence
Interventions
CPAP treatment, No CPAP treatment
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Sep 11, 2026, 10:26 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

NCT07500090
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
HBS-301 tablet, Placebo
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Peoria, Arizona • Redwood City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Clarithromycin for the Treatment of Hypersomnia

NCT01146600
View directory record Official record
Conditions
Hypersomnia, Idiopathic Hypersomnia, Narcolepsy
Interventions
Clarithromycin followed by placebo, Placebo then Clarithromycin
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea

NCT00307944
View directory record Official record
Conditions
Acid Reflux Disease, Obstructive Sleep Apnea
Interventions
Pantoprazole
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

NCT03624920
View directory record Official record
Conditions
Parkinson Disease
Interventions
THN102 Dosage A, THN102 Dosage B, THN102 Dosage C
Drug
Lead sponsor
Theranexus
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

NCT02512588
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
BTD-001, Placebo
Drug
Lead sponsor
Balance Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 3 Interventional

An Open Label Study of FT218 in Subjects With Narcolepsy

NCT04451668
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Somnolence, Sleep Disorder, Sleep Disturbance, Sleep Wake Disorders
Interventions
FT218
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Redwood City, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)

NCT06665230
View directory record Official record
Conditions
Healthy, Narcolepsy
Interventions
MK-6552, Modafinil
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 11, 2026, 10:26 PM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Results available

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

NCT04091438
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
TAK-925, TAK-925 Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
20
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 11, 2026, 10:26 PM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 11, 2026, 10:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 11, 2026, 10:26 PM EDT
Completed Phase 1 Interventional

A Study of HBS-201 (Pitolisant Delayed-release)

NCT07051252
View directory record Official record
Conditions
Narcolepsy
Interventions
HBS-201
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
San Ramon, California • Brandon, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 11, 2026, 10:26 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
34
States / cities
Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 11, 2026, 10:26 PM EDT